Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
08 août 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
29 juil. 2022 08h00 HE
|
Adamis Pharmaceuticals Corporation
ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on...
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
29 juil. 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety...
Adamis Pharmaceuticals Issues Letter to Stockholders
21 juil. 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
01 juin 2022 08h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Appoints Vickie Reed to Board of Directors
26 mai 2022 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of...
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
18 mai 2022 17h00 HE
|
Adamis Pharmaceuticals Corporation
David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE)...
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
16 mai 2022 16h35 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
09 mai 2022 17h56 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
31 mars 2022 16h49 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...